- AstraZeneca and Daiichi Sankyo’s Enhertu receives FDA approval for first-line use in HER2-positive breast cancer, in combination with Roche’s Perjeta. Approval based on positive data from phase III DESTINY-Breast09 study.
- Enhertu already approved for second-line treatment in 85+ countries and other HER2-targeted indications.
- AstraZeneca to pay Daiichi Sankyo $150 million milestone payment post-approval, with AZN shares up 36.3% over the past year.
- DESTINY-Breast09 study shows Enhertu-Perjeta combo significantly improves progression-free survival in HER2-positive metastatic breast cancer patients.
- AstraZeneca and Daiichi Sankyo global collaboration on Enhertu includes expansion to Datroway.
- AZN currently holds Zacks Rank #3 (Hold), with better-ranked biotech stocks like ANIP, CRMD, and CSTL at Zacks Rank #1 (Strong Buy).
- Zacks’ Research highlights a little-known satellite-based communications firm as a top pick for potential significant growth.
- Analysts forecast major revenue breakout in 2025 for the highlighted stock.
- Other Zacks’ top stock picks and runners-up available for free analysis.
- Disclaimer: Views expressed are the author’s and not necessarily Nasdaq’s.
Read more at Nasdaq: AZN, Daiichi’s Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)